drugset / Trial / NCT05928780
An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC in First-line Treatment (FUTURE-Trop2)
RandomizedParallel-groupOpen-labelTreatment
Summary
To explore the efficacy and safety of TROP2 in the treatment of ABC
Timeline
- Start
- 2023-07-01
- Primary completion
- 2024-03-01
- Completion
- 2025-09-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BP102 | Monoclonal antibody | 15 mg/kg | — |
| Subject | Camrelizumab | Monoclonal antibody | 200 mg | — |
| Subject | Fluzoparib | Small molecule | 150 mg | — |
| Subject | SG | Unknown | 10 mg/kg | — |
| Subject | SHR3680 | Unknown | 240 mg | — |